PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2023
CASE
AUTH/3752/3/23 Novo Nordisk

AUTH/3752/3/23: PMCPA Director/Media v Novo Nordisk (Observer articles on semaglutide/β€˜skinny jab’) – No breach

Five Observer articles alleged Novo Nordisk used payments, grants and PR to shape the obesity debate and influence NICE/NHS. PMCPA assessed multiple…

2022
CASE
AUTH/3719/12/22 GlaxoSmithKline

AUTH/3719/12/22: GSK – Trelegy website claims, NMA presentation and Ellipta device messaging

GSK’s Trelegy site and ERS leavepiece used broad superiority messaging and visuals that implied statistical significance where it wasn’t shown, plus an…

2021
CASE
ALK-Abelló ⭐ Case of the Week

ALK-AbellΓ³: Representative’s Facebook post promoted Jext (POM) to the public

An ALK-AbellΓ³ representative posted about Jext on Facebook with a link to the product website and urged people to share. PMCPA ruled…

2023
CASE
AUTH/3800/7/23 AstraZeneca

AUTH/3800/7/23: Employee complaint alleging MEGS used to promote Imfinzi (No breach) – AstraZeneca

Employee alleged Auxilium CRT (a MEGS) was used as disguised promotion to boost Imfinzi during COVID-19 and reflected poor culture. PMCPA Panel…

2023
CASE
AUTH/3786/6/23 AbbVie

AbbVie: senior medical employee mentioned Botox on national TV quiz show (AUTH/3786/6/23)

A senior UK-based AbbVie medical affairs employee referenced Botox on a national TV quiz show. PMCPA ruled this promoted a POM to…

2023
CASE
AUTH/3818/9/23 GlaxoSmithKline

AUTH/3818/9/23: Complainant v GSK β€” Allegations about a webpage (outwith scope of the Code)

PMCPA recorded a complaint about a GSK webpage. The case was concluded as outwith the scope of the ABPI Code of Practice,…

2021
CASE
AUTH/3824/09/2023 Novartis Pharmaceuticals UK

Novartis: GP alleged caller implied NHS England identity during promotional call (AUTH/3824/09/2023) – No breach

A GP alleged a caller acting for Novartis implied they were NHS England and only disclosed Novartis when challenged. Panel could not…

2021
CASE
A. Menarini Farmaceutica Internazionale S.r.l. ⭐ Case of the Week

A. Menarini breached Clause 26.1 after third-party X post showed β€œInvokana canagliflozin tablets” at diabetes conference

An events business employee posted a public X photo where β€œInvokana canagliflozin tablets” was legible on Menarini’s stand. PMCPA held this amounted…

2023
CASE
AUTH/3848/11/23 Gilead

Gilead: Conference Wi‑Fi landing page linked to US corporate site press release promoting investigational lenacapavir use (AUTH/3848/11/23)

Conference Wi‑Fi sponsored by Gilead redirected delegates to a US corporate homepage featuring a press release about lenacapavir for HIV prevention. Panel…

2024
CASE
AUTH/3926/6/24 Pfizer

Pfizer: employee β€˜liked/loved’ NHS LinkedIn posts naming voxelotor (Oxbryta) – promotion of a POM to the public (AUTH/3926/6/24)

PMCPA found Pfizer in breach after a UK employee β€˜liked/loved’ two NHS LinkedIn posts naming voxelotor and making benefit claims. The original…

2024
CASE
AUTH/3902/5/24 Theramex UK

Theramex congress booth discussion about linzagolix (Yselty): complaint about alleged off-label/availability promotion found no breach (AUTH/3902/5/24)

A UK doctor alleged a Theramex representative implied linzagolix was available and soon licensed for endometriosis at an Italy congress. PMCPA could…

2008
CASE
Pfizer

Pfizer letter requesting addition of Ecalta and Celsentri to hospital e-prescribing system ruled promotional without prescribing information

A hospital pharmacist complained about a Pfizer-authorised letter asking hospitals to add Ecalta and Celsentri to electronic prescribing/dispensing systems. The Panel ruled…

2008
CASE
Trinity-Chiesi Pharmaceuticals

Trinity-Chiesi letter promoting Clenil: omission of 200mcg cost comparison not misleading in Scottish context

A PCT pharmacist alleged a Clenil cost-comparison chart was misleading because it omitted 200mcg data. The Panel found the Scottish Drug Tariff…

2008
CASE
AUTH/2156/8/08 Sanofi

AUTH/2156/8/08: GlaxoSmithKline v Sanofi Pasteur MSD – Gardasil letter to health professionals

A letter about the UK HPV vaccine tender was ruled promotional for Gardasil, lacked prescribing information and adverse event reporting guidance, and…

2008
CASE
AUTH/2141/7/08 Sanofi ⭐ Case of the Week

AUTH/2141/7/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (24-hour efficacy and hypoglycaemia claims)

Complaint about Lantus promotional leavepieces and a mailer. Issues included β€œ24-hour efficacy” wording and comparative hypoglycaemia claims based on pooled observational data.…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training